References
- Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18(Suppl 1):i3–i8.
- National Cancer Insitute- Surveillance E, and End Results Program (SEER). Cancer stat facts: NHL – diffuse large B-cell lymphoma (DLBCL); 2016 [cited 2019 Oct 22]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html
- Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–795.
- Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
- Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011(1):498–505.
- Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. JCO. 2014;32(31):3490–3496.
- Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216–221.
- Chaganti S, Illidge T, Barrington S, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43–56.
- Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–v125.
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
- Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
- Gorovits B, Koren E. Immunogenicity of chimeric antigen receptor T-cell therapeutics. BioDrugs. 2019;33(3):275–284.
- Liu Y, Chen X, Han W, et al. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today. 2017;53(11):597–608.
- United States Food and Drug Administration (FDA). FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma; 2018 [cited 2019 Oct 22]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma
- United States Food and Drug Administration (FDA). Highlights of prescribing information: KYMRIAH™ (tisagenlecleucel); 2018 [cited 2019 Oct 28]. Available from: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert. —KYMRIAH.pdf
- Schuster SJ, Bishop MR, Tam CS, et al.; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
- O'Leary MC, Lu X, Huang Y, et al. FDA approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142–1146.
- NCT02445248: Study of efficacy and safety of CTL019 in adult DLBCL patients (JULIET) [cited 2020 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT02445248
- IBM Micromedex. Wholesale acquisition cost (WAC), REDBOOK; 2019 [cited 2019 Jun 23]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian
- Centers for Medicare & Medicaid Services (CMS). CMS Physician Fee Schedule; [cited 2019 Jun 23]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
- Premier Applied Sciences. Premier Healthcare Database; 2019 [cited 2019 Oct 24]. Available from: https://products.premierinc.com/downloads/PremierHealthcareDatabaseWhitepaper.pdf
- Centers for Medicare & Medicaid Services (CMS). CMS Outpatient Prospective Payment System (PPS); 2019 [cited 2019 Jun 23]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1695-FC.html
- Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) Inpatient database [cited 2019 Jun 23]. Available from: https://www.ahrq.gov/data/hcup/index.html
- Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Biol Blood Marrow Transplant. 2020;26(3):S41–S42.
- Yang H, Hao Y, Chai X, et al. Budget impact associated with the introduction of tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Meeting Abstracts - Academy of Managed Care Pharmacy Nexus 2018. J Manag Care Spec Pharm. 2018;24(10-a Suppl):S29. DOI:10.18553/jmcp.2018.24.10-a.s1
- Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105–2119.
- Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 2018;4(7):994–996.
- Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(5):1133–1142.
- Huntington S, Keshishian A, McGuire M, et al. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leuk Lymphoma. 2018;59(12):2880–2887.
- Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174(2):235–248.
- Kilgore K, Mohammadi I, Schroeder A, et al. Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: A first real-world look at patient characteristics, healthcare utilization and costs. 61st ASH Annual Meeting and Exposition; December 7-10, 2019. Orlando, FL, US, 2019.
- Institute for Clinical and Economic Review (ICER). ICER final evidence report: Chimeric antigen receptor T-cell therapy for B-cell cancers: Effectiveness and value; 2018 [cited 2019 Oct 30]. Available from: https://icer-review.org/wp-content/uploads/2017/07/ICER_CAR_T_Final_Evidence_Report_032318.pdf
- Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7(1):1601484.
- Institute for Clinical and Economic Review (ICER). ICER final evidence report: Voretigene neparvovec for biallelic RPE65-mediated retinal disease: Effectiveness and value; 2018 [cited 2019 Nov 26]. Available from: https://icer-review.org/wp-content/uploads/2017/06/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf
- Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80–86.
- Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLos One. 2018;13(4):e0196007.
- Copley-Merriman C, Stevinson K, Liu FX, et al. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine (Baltimore). 2018;97(31):e11736.
- Centers for Medicare & Medicaid Services (CMS). Fiscal Year (FY) 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) prospective payment system proposed rule and request for information 2020 [cited 2019 Nov 17]. Available from: https://www.cms.gov/newsroom/fact-sheets/fiscal-year-fy-2020-medicare-hospital-inpatient-prospective-payment-system-ipps-and-long-term-acute